media – Page 18 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

CSPC Pharmaceutical Group Limited ‘s clinical trial for the recombinant fully human anti-ACTRIIA/IIB monoclonal antibody has been approved

Beijing Business News (Reporter Wang Yinhao, Song Yuying) – On November 26th, Shigao Group announced that the recombinant fully human anti-ActRIIA/IIB monoclonal antibody drug (JMT206) developed by the group has been approved by the National Medical Products Administration and can conduct clinical trials in China. The announcement shows that this product can specifically bind to both activin receptor type IIA and type IIB simultaneously, blocking the binding of activin A, myostatin, and growth differentiation factor 11 to activin receptor type II, thereby inhibiting the activation of downstream signaling pathways, reducing muscle loss, and promoting the maintenance and growth of skeletal muscles, achieving the effect of muscle gain and fat loss. At the same time, this product can also assist GLP-1 receptor agonists in achieving higher-quality weight loss efficacy. The approved clinical indication for this approval is weight management for obese or overweight individuals with at least one weight-related comorbidity. https://finance.eastmoney.com/a/202511263575661579.html
- Source: drugdu
- 79
- November 27, 2025
CDMEE Chengdu

Organiser：Sichuan Provincial Hospital Association, Sichuan Medical Device Industry Association, Sichuan Rehabilitation Medicine Association Time： March 17 – 19, 2026 Address：No. 198, Shijicheng Road, Chengdu, Sichuan Province Exhibition hall：Chengdu Century City New International Convention & Exhibition Center Product range: Medical Equipment Exhibition Area: Imaging equipment, in vitro diagnostic reagents and instruments, disinfection and infection control series, medical electronic equipment, medical vehicles, operating room and emergency equipment, medical consumables and surgical consumables, medical maintenance parts and consumables, etc. Medical Laboratory Exhibition Area: Medical analysis systems, gene and life science instruments, laboratory case equipment and consumables, clinical laboratory equipment and consumables, blood collection management systems and blood transfusion supplies, blood and cell analysis systems, clinical laboratory equipment parts and maintenance consumables, etc. Rehabilitation and Well-being Exhibition Area: Sensory integration training equipment, disability aids and supplies, rehabilitation and physiotherapy equipment, sensory interaction equipment, assistive devices, etc.; sensory integration training equipment, disability equipment and supplies, ...
- Source: drugdu
- 104
- November 27, 2025
Fosun Pharma and Ruizhi Pharma Reach Strategic Cooperation

On November 25th, Fosun Pharma and Ruizhi Pharma…A strategic cooperation framework agreement signing ceremony was held in Shanghai. Li Xiang, Senior Vice President and CEO of the Global R&D Center of Fosun Pharma , stated that in the future, leveraging the full-chain R&D service capabilities of Ruizhi Pharma , Fosun Pharma is expected to further improve the efficiency and quality of its drug development across various drug types, accelerate the transformation of innovative achievements, and consolidate its competitive advantage in the field of innovative medicine. At the same time, the cooperation between the two parties sets a benchmark for the industry with a “technology-driven innovation platform + service platform” model, which will help promote the efficient integration of upstream and downstream resources in the industry chain, contribute to improving the overall level of new drug development in China, and bring more high-quality treatment options to more patients. https://finance.eastmoney.com/a/202511253574517765.html
- Source: drugdu
- 84
- November 26, 2025
Aurisco’s wholly-owned subsidiary received the marketing authorization for its Estradiol Tablets

November 25 – Aurisco (605116) announced that its wholly-owned subsidiary, Yangzhou Aurisco Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA) for Estradiol Tablets / Estradiol and Dydrogesterone Tablets Composite Packaging. The dosage form is tablets, with specifications as follows: each Estradiol Tablet contains 2mg of estradiol, and each Estradiol and Dydrogesterone Tablet contains 2mg of estradiol and 10mg of dydrogesterone. As of October 31, 2025, the cumulative R&D investment in this drug project by the company amounted to approximately RMB 12.64 million. This product is a dydrogesterone compound preparation originally developed by Abbott. It is used to treat perimenopausal syndrome caused by natural or surgical menopause. In 2015, the Estradiol Tablets / Estradiol and Dydrogesterone Tablets Composite Packaging, applied for by Abbott as an imported drug, was approved for marketing in China under the brand name “Femoston®”. Data from ...
- Source: drugdu
- 78
- November 26, 2025
Hengrui Pharma’s Ruikang Trastuzumab for Injection Wins Clinical Trial Approval

Beijing Business Today, Nov. 25 – Hengrui Pharmaceuticals announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for Ruikang Trastuzumab for Injection, approving the monotherapy clinical trial in patients with HER2-amplified solid tumors. According to the announcement, Ruikang Trastuzumab for Injection binds to and is internalized by HER2-expressing tumor cells. Within the tumor cell lysosomes, the toxin is released through protease cleavage, inducing cell cycle arrest and triggering tumor cell apoptosis. The released toxin exhibits high membrane permeability, enabling a bystander killing effect that further enhances anti-tumor efficacy. Ruikang Trastuzumab for Injection was approved for marketing in China in May 2025, indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) activating mutations who have previously received at least one line of systemic ...
- Source: drugdu
- 78
- November 26, 2025
Honz Pharmaceutical Co., Ltd. has received the approval notice for the clinical trial of the cough-relieving orange-red granules drug

Beijing Business News (Reporter Ding Ning) – On the evening of November 25th, Honz Pharmaceutical Co., Ltd. (300086) issued a statement, announcing that recently, the company’s “Cough Suppressant Juhong Granules” has obtained the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. The announcement shows that Cough Suppressant Juhong Granules is a product that the company has already produced and is currently on sale. It was originally a national second-level protected traditional Chinese medicine variety (with a protection period until September 13, 2016), and its current indications are “clearing the lungs, suppressing cough, and resolving phlegm. It is used for cough with excessive phlegm, chest fullness, shortness of breath, dry throat and itchy throat caused by phlegm heat blocking the lungs.” Based on the latest clinical research and expert consensus, the company submitted a clinical trial application to add a new indication of “acute exacerbation of chronic ...
- Source: drugdu
- 77
- November 26, 2025
Novo Nordisk has released the clinical trial data of its new diabetes drug, amycretin.

Novo Nordisk has released the clinical trial data for the new diabetes drug amycretin, showing that the drug not only lowers blood sugar but also has a significant weight loss effect. The trial results indicate that the amycretin injection, administered once a week, can help patients lose up to 14.5% of their weight within 36 weeks; the oral formulation can achieve a weight loss of up to 10.1% per day. This positive news has pushed the stock price of Novo Nordisk’s US shares to rise, recovering most of the losses it suffered previously due to the failure of its Ozempic oral version to slow the progression of Alzheimer’s disease in two clinical trials. Amycretin is a key component of Novo Nordisk’s new drug portfolio, integrating two weight loss mechanisms into a single molecule, aiming to improve the company’s competitive position in the field of obesity treatment. https://finance.eastmoney.com/a/202511263574807587.html
- Source: drugdu
- 61
- November 26, 2025
【EXPERT Q&A】Is it difficult to obtain a medical device business license? How can one apply for it?

Drugdu.com expert’s response: The handling of medical device business licenses presents certain difficulties, but with systematic preparation and standardized operations, it can be completed successfully. The main challenges lie in complex policies and regulations, stringent technical requirements, cumbersome material preparation, a lengthy approval process, and a scarcity of professional talent. However, enterprises can reduce these difficulties through advance planning, standardized operations, and seeking professional support. The following is a detailed analysis: Difficulties in Handling Complex Policies and Regulations: The handling of medical device business licenses involves numerous regulations such as the “Regulations on the Supervision and Administration of Medical Devices” and the “Measures for the Administration of Medical Device Registration.” These regulations are complex and frequently updated, requiring enterprises to continuously learn and adapt. Otherwise, they may easily fail in their applications due to non-compliant operations. Stringent Technical Requirements: During the handling process, sufficient technical materials and proofs must be ...
- Source: drugdu
- 95
- November 26, 2025
Mabwell Biotech’s innovative CDH17-targeted ADC drug 7MW4911 has been successfully administered to its first patient

November 25th, Mabwell Biotechnology announced on its official WeChat account that it has developed an innovative CDH17-targeting ADC drug.(Development code: 7MW4911) The first patient was recently dosed in a Phase I/II clinical trial for advanced solid tumors. Preclinical studies showed that 7MW4911 exhibited potent antitumor activity in CDX/PDX models of various gastrointestinal tumors; in multidrug-resistant models, its antitumor effect was significantly superior to MMAE/DXd ADCs, and it could reverse tumor progression after treatment with such ADCs, highlighting its advantages in the treatment of drug-resistant tumors. https://finance.eastmoney.com/a/202511253573547662.html
- Source: drugdu
- 93
- November 25, 2025
Approval Received for Marketing Authorization of Edoxaban Tosylate API

Jiuzhou PharmaceuticalThe announcement states that Zhejiang Jiuzhou Pharmaceutical Co., Ltd. received chemical raw materials from the National Medical Products Administration.The company recently received the Approval Notice for Marketing Authorization of its chemical active pharmaceutical ingredient, edoxaban tosylate. This oral anticoagulant is primarily used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat or prevent deep vein thrombosis and pulmonary embolism. This approval indicates that the active pharmaceutical ingredient meets the relevant requirements for national drug registration and will further enrich the company’s product portfolio and enhance its market competitiveness. The above matters will not have a significant impact on the company’s performance in the short term. https://finance.eastmoney.com/a/202511243572990379.html
- Source: drugdu
- 82
- November 25, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.